Innovent Biologics, ASK Pharm announce China’s NMPA approval of limertinib to treat metastatic EGFR T790M-mutated NSCLCr: San Francisco Saturday, January 18, 2025, 09:00 Hrs [IS ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...